Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Current and Future Management Strategies of Patients with Oesophageal Cancer

ESMO-Webinar-Management-Strategies-Webinar-1000x250
Live on
15 Mar 2022 at 18:30 CET

It is with great pleasure that I invite you to participate in this ESMO webinar that will focus on current and future strategies in the management of patients with oesophageal cancer.

This webinar aims to provide an overview of the best standard approach for patients with localised oesophageal cancer, practical considerations selecting optimal sequence of immune checkpoint inhibitors for the treatment of patients with advanced oesophageal cancer, as well as use of different predictive biomarkers to maximise benefit of immune checkpoint inhibitors.

We will begin with a lecture on optimal multimodality management of localised oesophageal cancer. Next, we have a lecture on the role of immune checkpoint inhibitors in the continuum of care for patients with advanced oesophageal cancer. Finally, we will present a clinical case and focus on the role of biomarkers for prognostication and prediction of benefit from immunotherapeutic approaches. The lectures will be followed by a live discussion where we will also answer questions from the audience.

The programme is designed to provide an overview of the latest evidence in the management of patients with oesophageal cancer, offer expert opinion exchange and provide some important considerations about future strategies in this field. I strongly encourage and invite you to register and join us all in this ESMO activity.

Prof. Andrés Cervantes

Hospital Clinic Universitario
Biomedical Research institute INCLIVA
University of Valencia

Speakers

Programme

Time

Title

Speaker

5 min

Welcome and Introduction

Andrés Cervantes

15 min

Optimal multimodality management of localised oesophageal cancer

Radka Obermannová

15 min

The role of immune checkpoint inhibitors in the continuum of care for patients with advanced oesophageal cancer

Ian Chau

15 min

Presentation of a clinical case and management focusing on the role of biomarkers for prognostication and prediction of benefit from immunotherapeutic approaches

Sarah Derks

15 min

Live discussion, Q&A, and Conclusions

All

A certificate of attendance and 1 ESMO MORA category point will be awarded for live attendance at this event.

Learning objectives:

  • To understand the best standard approach for patients with localised oesophageal cancer
  • To select the optimal sequence of Immune Checkpoint Inhibitors when treating advanced oesophageal cancer
  • To properly use different predictive biomarkers to get the maximum benefit of Immune Checkpoint Inhibitors

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.